Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical non-inferiority to vancomycin/linezolid

Frederick Wittkea*, Catherine Vincenta, James Chenb, Barry Hellerc, Heidi Kablerd, J. Scott Overcashe, François Leylavergnea, Guennaelle Dieppoisa

Antimicrobial Agents and Chemotherapy, Vol. 64, Issue 10

aDebiopharm International SA, Lausanne, Switzerland
bSouthbay Pharma Research, Buena Park, California, USA
cLong Beach Clinical Trials, Long Beach, California, USA
dSunrise Hospital and Medical Center, Las Vegas, Nevada, USA
eeStudySite, San Diego, California, USA

*Present address: Frederick Wittke, European Clinical Development Vaccines MSD, Weystrasse 20,
6006 Lucerne, Switzerland